SCHEMBL5225561

SCHEMBL5225561

CCCCC1(CCCC)CS(=O)(=O)c2cc(OC)ccc2N(c2ccc([N+](=O)[O-])cc2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
SLC10A2 Q12908 4/20 0.39
MAPT P10636 6/20 0.38
LMNA P02545 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
HTT P42858 3/20 0.37
ALDH1A1 P00352 4/20 0.36
HPGD P15428 1/20 0.36
ELANE P08246 1/20 0.36
SNCA P37840 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CNR1 P21554 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
NPC1 O15118 1/20 0.35
CRHBP P24387 1/20 0.35
GFER P55789 1/20 0.35
CRHR2 Q13324 1/20 0.35
USP8 P40818 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223555 0.81 SNCA (0.43) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL8026030 0.68 SLC6A2 (0.51) SLC10A2ELANEKDM4E
SCHEMBL8014423 0.65 SLC6A2 (0.43) MAPTLMNAALDH1A1HPGDELANE
SCHEMBL7090524 0.64 SLC10A2 (0.41) SLC10A2KDM4E
SCHEMBL6843767 0.64 ELANE (0.40) MEN1KMT2AMAPTELANEKDM4E
SCHEMBL4254039 0.63 SCN2A (0.61) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6990676 0.62 LMNA (0.41) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL30728278 0.62 SLC10A2 (0.47) SLC10A2LMNAALDH1A1HPGD
SCHEMBL8025864 0.60 SLC6A2 (0.48) LMNASMN1; SMN2ALDH1A1HPGDELANE
SCHEMBL9824170 0.59 ALDH1A1 (0.53) MEN1KMT2AMAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1345918-B1 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS ASTRAZENECA AB (SE) 2007-04-18 EP disclosed
US-7192945-B2 Benzothiazepine derivatives ASTRAZENECA AB (SE) 2007-03-20 US disclosed
US-20040067933-A1 Chemical compounds ELOBIX AB (SE) 2004-04-08 US disclosed
EP-1345918-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-09-24 EP disclosed
WO-2002050051-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067933-A1 Chemical compounds SLC10A2, SLC10A1, ABCB11 MEN1 1329/4885KMT2A 2975/4885SLC10A2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.